Erlotinib in combination with bevacizumab has potential benefit in non-small cell lung cancer: a systematic review and meta-analysis of randomized clinical trials
B Zhao, W Zhang, D Yu, J Xu, Y Wei - Lung Cancer, 2018 - Elsevier
Objectives A role for erlotinib and bevacizumab as single agents has been established in
the treatment of non-small cell lung cancer (NSCLC). However, the efficacy and safety of …
the treatment of non-small cell lung cancer (NSCLC). However, the efficacy and safety of …
Comparing efficacy of erlotinib and bevacizumab combination with erlotinib monotherapy in patients with advanced non-small cell lung cancer (NSCLC): A systematic …
P Sakharkar, S Kurup - Diseases, 2023 - mdpi.com
The objective of this systematic review and meta-analysis was to assess and contrast the
efficacy and safety of combining erlotinib and bevacizumab with erlotinib alone in the …
efficacy and safety of combining erlotinib and bevacizumab with erlotinib alone in the …
Efficacy and safety of bevacizumab plus erlotinib versus bevacizumab or erlotinib alone in the treatment of non-small-cell lung cancer: a systematic review and meta …
S Zhang, X Mao, H Wang, F Cai, J Xu - BMJ open, 2016 - bmjopen.bmj.com
Objectives Bevacizumab and erlotinib inhibit different tumour growth pathways, and both
exhibit beneficial effects in the treatment of non-small-cell lung cancer (NSCLC). However …
exhibit beneficial effects in the treatment of non-small-cell lung cancer (NSCLC). However …
Efficacy and safety of erlotinib combined with bevacizumab in the treatment of non-small cell lung cancer: A systematic review and meta-analysis
K Zhou, S Zhao, W Guo, L Ding - Medicine, 2020 - journals.lww.com
Background: Non-small cell lung cancer (NSCLC) has a poor prognosis despite
conventional treatments of surgery, radiotherapy, and chemotherapy. Small-molecule …
conventional treatments of surgery, radiotherapy, and chemotherapy. Small-molecule …
Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-small-cell lung cancer: a systematic review and meta-analysis of …
W Deng, K Wang, Y Jiang, D Li, C Bao, J Luo, L Liu… - BMJ open, 2022 - bmjopen.bmj.com
Objectives Combination treatment with erlotinib plus bevacizumab has the potential to
become a standard treatment regimen for patients with epidermal growth factor receptor …
become a standard treatment regimen for patients with epidermal growth factor receptor …
Erlotinib with or without bevacizumab as a first‐line therapy for patients with advanced nonsquamous epidermal growth factor receptor‐positive non‐small cell lung …
Y Hosomi, T Seto, M Nishio, K Goto… - Thoracic …, 2022 - Wiley Online Library
Background In the phase II JO25567 study (JapicCTI‐111390), erlotinib plus bevacizumab
demonstrated a significant clinical benefit in Japanese patients with epidermal growth factor …
demonstrated a significant clinical benefit in Japanese patients with epidermal growth factor …
[HTML][HTML] A phase II study of erlotinib in combination with bevacizumab versus chemotherapy plus bevacizumab in the first-line treatment of advanced non-squamous …
T Ciuleanu, CM Tsai, CJ Tsao, J Milanowski… - Lung Cancer, 2013 - Elsevier
Background Molecularly targeted agents for non-small cell lung cancer (NSCLC) can
provide similar efficacy to chemotherapy without chemotherapy-associated toxicities …
provide similar efficacy to chemotherapy without chemotherapy-associated toxicities …
Tyrosine kinase inhibitor combination therapy in first-line treatment of non-small-cell lung cancer: systematic review and network meta-analysis
S Batson, SA Mitchell, R Windisch… - OncoTargets and …, 2017 - Taylor & Francis
Introduction The introduction of epidermal growth factor receptor tyrosine kinase inhibitors
(EGFR-TKIs) has improved the outlook for patients with advanced non-small-cell lung …
(EGFR-TKIs) has improved the outlook for patients with advanced non-small-cell lung …
A randomized phase III study of combining erlotinib with bevacizumab and panitumumab versus erlotinib alone as second-line therapy for Chinese patients with non …
Y Wang, H Wang, Y Jiang, Y Zhang, X Wang - Biomedicine & …, 2017 - Elsevier
Purpose In this phase III clinical study, we assessed the clinical outcomes of combining
erlotinib with bevacizumab and panitumumab as second-line chemotherapy for patients with …
erlotinib with bevacizumab and panitumumab as second-line chemotherapy for patients with …
Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double …
Background Bevacizumab and erlotinib target different tumour growth pathways with little
overlap in their toxic-effect profiles. On the basis of promising results from a phase 1/2 trial …
overlap in their toxic-effect profiles. On the basis of promising results from a phase 1/2 trial …
相关搜索
- lung cancer meta analysis
- erlotinib in combination meta analysis
- efficacy and safety meta analysis
- lung cancer erlotinib with bevacizumab
- lung cancer efficacy and safety
- bevacizumab in the treatment meta analysis
- lung cancer chinese patients
- efficacy and safety erlotinib alone
- chemotherapy alone meta analysis
- erlotinib with bevacizumab chinese patients
- efficacy of erlotinib bevacizumab combination
- phase ii study of erlotinib
- survival in patients effect of erlotinib
- combination with bevacizumab meta analysis
- safety of erlotinib meta analysis
- erlotinib alone meta analysis